Showing results (211-220 of 223) with videos related to

Sort By:
Pageof 23
Nature Communications|June 23, 2026
Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trialHejia Henry Wang, Amanda L Huff, S Daniel Haldar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2024
Next-Generation Sequencing-Based MSI Scoring Predicts Benefit in Mismatch Repair-Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1DJonathan D Schoenfeld, Nilofer S Azad, Jacob Gross, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2019
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) StudyNilofer S Azad, Robert J Gray, Michael J Overman, et al.
Cancer|February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trialMichael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
Oncoimmunology|November 15, 2021
Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resectionDaniel Delitto, Daniel J Zabransky, Fangluo Chen, et al.
The Journal of Clinical Investigation|December 15, 2021
Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancersMark Yarchoan, Leslie Cope, Amanda N Ruggieri, et al.
The New England Journal of Medicine|June 2, 2015
PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyDung T Le, Jennifer N Uram, Hao Wang, et al.
JCI Insight|June 26, 2025
Spatial proteomics and transcriptomics reveal early immune cell organization in pancreatic intraepithelial neoplasiaMelissa R Lyman, Jacob T Mitchell, Sidharth Raghavan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2020
Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic AdenocarcinomaLei Zheng, Ding Ding, Barish H Edil, et al.
Nature Communications|February 10, 2026
Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trialAmanda L Huff, S Daniel Haldar, Alexander A Gergis, et al.
Pageof 23